SCHEMBL1676385

SCHEMBL1676385

O=C(O)c1ccc(Cn2cc(-c3ccc(Cl)cc3Cl)nc2C=Cc2ccc(-c3ccc(F)c(F)c3)cc2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
RAB9A P51151 2/20 0.45
NPC1 O15118 1/20 0.45
CRHBP P24387 1/20 0.45
CRHR2 Q13324 1/20 0.45
ENPP2 Q13822 1/20 0.43
SRD5A2 P31213 1/20 0.40
MARS1 P56192 4/20 0.35
MEN1 O00255 2/20 0.35
HPGD P15428 2/20 0.35
KMT2A Q03164 2/20 0.35
PPARG P37231 1/20 0.35
NCOA2 Q15596 1/20 0.35
NCOA1 Q15788 1/20 0.35
NCOA3 Q9Y6Q9 1/20 0.35
EP300 Q09472 1/20 0.35
DPP4 P27487 1/20 0.35
LMNA P02545 1/20 0.35
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1676383 1.00 KDM4E (0.45) KDM4ESMN1; SMN2RAB9ANPC1CRHBP
SCHEMBL1481186 0.90 SMN1; SMN2 (0.47) KDM4ESMN1; SMN2RAB9ANPC1CRHBP
SCHEMBL1481188 0.90 SMN1; SMN2 (0.47) KDM4ESMN1; SMN2RAB9ANPC1CRHBP
SCHEMBL1676288 0.90 DRD2 (0.46) EP300POLBCNR1MDM2CNR2
SCHEMBL1676289 0.90 DRD2 (0.46) EP300POLBCNR1MDM2CNR2
SCHEMBL1482017 0.90 KDM4E (0.45) KDM4ESMN1; SMN2RAB9ANPC1CRHBP
SCHEMBL1482014 0.90 KDM4E (0.45) KDM4ESMN1; SMN2RAB9ANPC1CRHBP
SCHEMBL1481289 0.89 RAB9A (0.44) KDM4ESMN1; SMN2RAB9ANPC1CRHBP
SCHEMBL1481287 0.89 RAB9A (0.44) KDM4ESMN1; SMN2RAB9ANPC1CRHBP
SCHEMBL1676214 0.88 KDM4E (0.44) KDM4ESMN1; SMN2RAB9ANPC1CRHBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110092553-A1 Substituted Azole Derivatives, Compositions, and Methods of Use TRANSTECH PHARMA, INC. (US) 2011-04-21 US disclosed
EP-1730118-A1 SUBSTITUTED AZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE Transtech Pharma, Inc. (US) 2006-12-13 EP disclosed
WO-2005080346-A1 SUBSTITUTED AZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE TRANSTECH PHARMA, INC. (US) 2005-09-01 WO disclosed
US-20050187277-A1 Substituted azole derivatives, compositions, and methods of use TRANSTECH PHARMA, INC. 2005-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110092553-A1 Substituted Azole Derivatives, Compositions, and Methods of Use PTPRO, PTPN5, PTPRE KDM4E 733/4885SMN1; SMN2 4417/4885RAB9A 3396/4885
US-20050187277-A1 Substituted azole derivatives, compositions, and methods of use PTPRO, PTPN5, PTPRE KDM4E 733/4885SMN1; SMN2 4417/4885RAB9A 3396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.